ISG posts strong growth, releases NT-based software

Article

ISG posts strong growth, releases NT-based softwareMedical imaging and PACS software developer ISG Technologies reported strong financial results for its 1998 fiscal third quarter. The company realized a 16% increase in revenue for the period

ISG posts strong growth, releases NT-based software

Medical imaging and PACS software developer ISG Technologies reported strong financial results for its 1998 fiscal third quarter. The company realized a 16% increase in revenue for the period (end-March).

Revenues for the quarter were $9.1 million (Canadian), compared with $7.8 million reported in the same period last year. Net income was $108,000, compared with a net loss of $354,000 in 1997. The firm attributed the quarterly revenue growth to sales of platforms, postprocessing workstation software licenses, and contract engineering activities.

In other ISG news, the Mississauga, Ontario-based company formally released version 3.0 of its VR line of PACS viewing software. ISG demonstrated the Windows NT-based version of the software at the 1997 Radiological Society of North America meeting (PNN 1/98).

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.